Investors
eRecent News
- [2022-12-16] Delcath Systems Announces Inducement of Grant Under NASDAQ Listing Rule 5635(C)(4)
- [2022-12-13] Delcath Systems Closes Private Placement of $6.2 Million
- [2022-12-08] Delcath Systems Announces Private Placement of $6.2 Million
- [2022-12-05] Results of a Single Center Study on Delcath’s CHEMOSAT® Hepatic Delivery System In the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental Metastasis
- [2022-11-09] Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Download
View our Corporate Presentation
Disclaimer
You are about to review presentations, reports, filings and/or other materials regarding Delcath Systems, Inc. (NASDAQ: DCTH) that contain time-sensitive information. The information contained therein is only current as of the date thereof. Delcath expressly disclaims any obligation to review, update or correct these materials after the date thereof. Delcath may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice. Certain statements made on this Web site or in materials accessed in or through this section of our Web site are “forward–looking statements,” which are subject to risks and uncertainties, and Delcath’s actual results may differ (possibly materially) from those indicated in such statements. Data Provided by Thomson Reuters.
Delcath Systems, Inc. (NASDAQ-DCTH) is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.